Total raised
$10.5M
Last: Series B 2018-03
Stage
Series B
Founded
2013
Headcount
4
HQ
Ness Ziona
Sector
Health Tech & Life Sciences
About
SmartZyme Biopharma develops novel enzymesfor a variety of medical applications. Based on its proprietary proteinengineering platform, the Provolution, the companydesigns enzymes for improved clinical performanceby engineering them for efficacy and safety. Initially, SmartZyme is focusing on products for diabetes patients, including glucose monitoring test strips and patches. TheProvolution system combines advanced computationalmethods with a random mutagenesis approach, processingmultiple protein characteristics that are required for optimalperformance.
Funding history · 3 rounds · $10.5M total
2018-03
Series B
Undisclosed
2016-01
Undisclosed
$6.5M
2014-10
Undisclosed
$4.0M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the current operational status of SmartZyme Biopharma?
- SmartZyme Biopharma is currently inactive, having ceased operations in August 2024.
- When was SmartZyme Biopharma founded and where is it headquartered?
- SmartZyme Biopharma was founded in November 2013 and is headquartered in Ness Ziona, Israel.
- What was the total amount of funding raised by SmartZyme Biopharma?
- SmartZyme Biopharma raised a total of $10.5 million across its funding rounds. For a full financing history, please refer to startupim.
- Which investor participated in SmartZyme Biopharma's October 2014 funding round?
- In October 2014, SmartZyme Biopharma raised $4 million in an undisclosed round, with OrbiMed as an investor.
- Which investors participated in SmartZyme Biopharma's Series B round in March 2018?
- In March 2018, SmartZyme Biopharma's Series B round included investments from Virtus Inspire Ventures and OrbiMed.
- What was the role of WallachBeth Capital, LLC in SmartZyme's Series B-1 offering?
- According to a March 2018 news release, WallachBeth Capital, LLC acted as the sole placement agent for SmartZyme's ongoing Series B-1 offering.
- What is SmartZyme Biopharma's primary focus in product development?
- SmartZyme Biopharma develops novel enzymes for medical applications, initially focusing on products for diabetes patients, including glucose monitoring test strips and patches, using its proprietary Provolution platform.
- What is the estimated employee count for SmartZyme Biopharma?
- SmartZyme Biopharma has an estimated employee count in the range of 1-10, with an exact count of 4 employees.
- What was the partnership announced in December 2018 involving a SmartZyme Biopharma spin-off?
- In December 2018, Carnot BioSciences, a spin-off of SmartZyme Biopharma, partnered with HemoShear Therapeutics to develop protein-based therapeutics for rare metabolic diseases.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B
Highlights
1 PatentsVerified
Tags
wearablediabetesbioinformaticschronic-patientswearable